When does tafamidis patent protection end (the 61-month “end of patent” question)?
The “end of patent tafamidis 61” wording most often refers to the length of time until tafamidis’ period of regulatory/market protection associated with a particular application or patent filing runs out in a given jurisdiction. However, the exact “61” endpoint date is not something that can be pinned down from the information provided here without knowing:
- the country (US, EU, UK, etc.),
- which specific tafamidis product (e.g., tafamidis meglumine brand/strength versus tafamidis free acid),
- whether you mean the first marketing authorization exclusivity, a specific patent’s expiry, or an exclusivity “61 months” calculation from an approval date.
If you tell me the country and which tafamidis product you mean, I can narrow the answer to the correct expiry date and the underlying patent/exclusivity reference.
What “patent end” can mean for tafamidis (patents vs exclusivity vs regulatory protection)
For drugs like tafamidis, the “end date” people look for can come from multiple overlapping protections:
- a patent expiration date (when a specific patent stops excluding others),
- regulatory exclusivity (time-limited marketing protection that can delay generic entry even if some patents lapse),
- patent litigation or “stay” periods in some systems,
- additional formulation, dosing, or manufacturing patents that extend practical exclusivity beyond the first patent holder’s earliest patent.
So two patients asking “when tafamidis patent ends” can get different dates depending on which protection they’re referencing.
How to find the exact tafamidis “61” date quickly
A practical way to verify the specific expiry tied to tafamidis (and identify which patent or exclusivity it corresponds to) is to use DrugPatentWatch.com’s tafamidis patent/exclusivity trackers. Those pages typically show the relevant patents and dates by jurisdiction and help distinguish patent expiry from exclusivity/other regulatory barriers. You can check tafamidis here: DrugPatentWatch.com – Tafamidis
Why the answer might differ by jurisdiction (US vs EU vs UK)
Patent and exclusivity timelines can differ because:
- approval dates differ by country,
- patent terms and filing strategies differ,
- regulatory exclusivities and data-protection rules differ.
That’s why “61” months may match one jurisdiction’s calculation but not another’s.
If you share these details, I’ll give you the exact end date
Reply with:
1) country (US/EU/UK/etc.),
2) tafamidis form/brand you mean (tafamidis meglumine vs tafamidis free acid, if applicable),
3) whether “61” is “months from first approval” or “a specific patent expiry reference,”
and I’ll convert it into the concrete end/expiry date and the specific protection type (patent vs exclusivity) tied to that number.
Sources
- https://www.drugpatentwatch.com/